Dr. Joseph Michael Dula Iii is a pharmacist who is specialized in Pharmacotherapy in Dublin, Ohio. Patients can reach him at 5050 Bradenton Ave, Pharmacy Systems, Inc., Dublin or contact him on 614-766-0101. Active license number of Dr. Joseph Michael Dula Iii is 03-3-26856 for Pharmacotherapy in Ohio. Dr. Joseph Michael Dula Iii is a licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing pharmacotherapeutic care of patients, by developing, implementing, monitoring, and modifying complex treatment plans, providing advanced level education and consultation, and collaborating with other health professionals in the management of therapy.
Complete Profile:
Dr. Joseph Michael Dula Iii speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Dr. Joseph Michael Dula Iii are as mentioned below.
NPI Number:
1770576498
NPI Enumeration Date:
28 Aug, 2005
NPI Last Update On:
19 Aug, 2009
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Joseph Michael Dula Iii are as mentioned below.
Specialization
License Number
State
Status
Pharmacotherapy
03-3-26856
Ohio
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
6221 Acacia Dr, Hilliard, Ohio
Zip:
43026-6197
Phone Number:
216-374-4533
Fax Number:
--
Patients can reach Dr. Joseph Michael Dula Iii at 5050 Bradenton Ave, Pharmacy Systems, Inc., Dublin, Ohio or can call on phone at 614-766-0101.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 13 May, 2024.